Phreesia, Inc. (NYSE:PHR – Get Free Report) SVP Amy Beth Vanduyn sold 604 shares of Phreesia stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $26.98, for a total transaction of $16,295.92. Following the sale, the senior vice president now directly owns 115,029 shares of the company’s stock, valued at $3,103,482.42. This represents a 0.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Amy Beth Vanduyn also recently made the following trade(s):
- On Monday, January 6th, Amy Beth Vanduyn sold 1,311 shares of Phreesia stock. The stock was sold at an average price of $26.61, for a total value of $34,885.71.
- On Tuesday, December 3rd, Amy Beth Vanduyn sold 25,447 shares of Phreesia stock. The stock was sold at an average price of $20.93, for a total value of $532,605.71.
Phreesia Stock Performance
PHR traded up $0.44 on Friday, hitting $27.24. 309,924 shares of the company’s stock were exchanged, compared to its average volume of 382,284. The firm has a market cap of $1.58 billion, a PE ratio of -18.53 and a beta of 0.94. The stock has a fifty day moving average of $23.42 and a two-hundred day moving average of $22.77. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $29.16. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the company. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Robert W. Baird reduced their target price on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Truist Financial boosted their target price on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research note on Friday, January 10th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $31.00.
View Our Latest Report on Phreesia
Hedge Funds Weigh In On Phreesia
A number of large investors have recently made changes to their positions in PHR. Versor Investments LP acquired a new stake in Phreesia in the third quarter valued at approximately $694,000. Zacks Investment Management acquired a new stake in shares of Phreesia in the third quarter worth $631,000. Sei Investments Co. increased its holdings in shares of Phreesia by 135.3% during the 2nd quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock worth $3,505,000 after purchasing an additional 95,058 shares during the period. State Street Corp lifted its position in shares of Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after acquiring an additional 88,517 shares during the period. Finally, Franklin Resources Inc. lifted its holdings in shares of Phreesia by 3.0% during the 3rd quarter. Franklin Resources Inc. now owns 1,497,631 shares of the company’s stock worth $31,495,000 after acquiring an additional 42,973 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
See Also
- Five stocks we like better than Phreesia
- Using the MarketBeat Stock Split Calculator
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- What Are the FAANG Stocks and Are They Good Investments?
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.